Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #63 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Gufic Biosciences Limited (this stock) | 4,209 | 57.3 | 9.7% | 18.3% | 0.02% | 53 | 8 | 51 |
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 261 | 30 | 22 | ₹ |
| March 31, 2026 | 252 | 29 | 22 | ₹ |
| Dec. 31, 2025 | 231 | 18 | 12 | ₹ |
| Sept. 30, 2025 | 237 | 23 | 17 | ₹ |
| June 30, 2025 | 224 | 17 | 13 | ₹ |
| March 31, 2025 | 205 | 11 | 8 | ₹ |
| Dec. 31, 2024 | 208 | 26 | 19 | ₹ |
| Sept. 30, 2024 | 204 | 29 | 22 | ₹ |
| June 30, 2024 | 203 | 28 | 21 | ₹ |
| March 31, 2024 | 195 | 27 | 20 | ₹ |
| Dec. 31, 2023 | 202 | 30 | 22 | ₹ |
| Sept. 30, 2023 | 215 | 31 | 23 | ₹ |
The detailed income statement is standalone-only: the consolidated feed carries just revenue, PBT and net profit.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 944 | 87 | 64 |
| March 31, 2025 | 820 | 94 | 70 |
| March 31, 2024 | 807 | 116 | 86 |
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 45 | -31 | 32 | 31 | 14 |
| March 31, 2025 | 123 | -71 | -37 | 76 | 47 |
| March 31, 2024 | -7 | -102 | 82 | 113 | -120 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,342 | 665 | 655 | 280 | 105 | 802 | 518 | 62 | 485 | 324 |
| March 31, 2025 | 1,169 | 601 | 591 | 180 | 130 | 625 | 388 | 16 | 500 | 217 |
| March 31, 2024 | — | — | — | — | — | — | — | — | — | — |
